United Kingdom & Merck & Co.

United Kingdom: The UK's NHS would need to approve the treatment for availability, and UK experts commented on the results.

Merck & Co.: Merck co-developed the vaccine and provided Pembrolizumab. The positive results expand its cancer portfolio and could offset future patent losses on Pembrolizumab. Merck's shares rose about 11%.

United Kingdom: The United Kingdom is providing up to £20 million to contain the Ebola outbreak in the Democratic Republic of the Congo and Uganda, supporting international efforts and frontline health workers.

Merck & Co.: Merck & Co.'s approved vaccine Ervebo for the Zaire strain of Ebola is referenced as a technological precedent for IAVI's Bundibugyo vaccine candidate.

United Kingdom: Recently introduced a four-in-one MMRV vaccine, showing a trend toward combination shots, not separation.

Merck & Co.: Manufacturer of the MMR vaccine, stated no scientific benefit to splitting it. Faces potential regulatory and market pressure if separate vaccines are developed, but currently no immediate financial impact.

United Kingdom: Sterling strengthens against weaker dollar.

Merck & Co.: Merck jumped 9.7% following the positive cancer vaccine data, boosting its outlook.

United Kingdom: The United Kingdom>>> is one of multiple nations that have implemented travel restrictions in response to the Ebola outbreak, indicating a global concern.

Merck & Co.: Merck & Co.>>>'s Ervebo vaccine, effective against the Zaire strain of Ebola, is being considered for potential use against the Uganda — Bundibugyo strain, though its efficacy is still under assessment.